All In Biotech

Drug Trial Radar · NCT07933458

A Study to Evaluate the Safety of Subunit Influenza Vaccine in People Aged 6 Months and Older

A Post-Marketing, Open-Label, Single-Arm Observational Study to Evaluate the Safety and Vaccination Influencing Factors of Subunit Influenza Vaccine in Individuals Aged 6 Months and Older

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

7,000

Planned (sponsor's estimate)

Start

Sep 4, 2026

Primary completion

Mar 31, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Ab&B Bio-tech Co., Ltd.JSAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ganzhou Center for Disease Control and Prevention (Ganzhou Health Comprehensive Supervision and Law Enforcement Bureau)
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a post-marketing, prospective observational study to evaluate the safety of a subunit influenza vaccine and the factors influencing influenza vaccination in individuals aged 6 months and older. A total of 7,000 vaccinated participants will be divided into Subgroup A (1,000 participants, active surveillance) and Subgroup B (6,000 participants, passive surveillance), and monitored for adverse events and serious adverse events within 28 days after vaccination. Participants in Subgroup A will additionally complete an electronic questionnaire on their knowledge of influenza and factors influencing their vaccination decisions.

Conditions

  • Influenza

Interventions

  • subunit influenza vaccineBiological

    Participants will receive one dose of Subunit Influenza Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of AEs and ADRsTime frame: Within 28 days post-vaccination
  2. Occurrence of SAEsTime frame: Within 28 days post-vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ganzhou Center for Disease Control and Prevention (Ganzhou Health Comprehensive Supervision and Law Enforcement Bureau)

    Ganzhou, Jiangxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.